SaRNA

TriLink BioTechnologies® and Lonza Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology

Retrieved on: 
Dienstag, April 30, 2024
Research, General Health, Pharmaceutical, Oncology, Infectious Diseases, Clinical Trials, Science, Cardiology, Biotechnology, Neurology, Other Science, Health, AG, Vaccine, SaRNA, Messenger

This agreement with Lonza strengthens TriLink’s objective to drive greater access to CleanCap® mRNA capping technologies as the demand for mRNA – a promising therapeutic modality – continues to grow.

Key Points: 
  • This agreement with Lonza strengthens TriLink’s objective to drive greater access to CleanCap® mRNA capping technologies as the demand for mRNA – a promising therapeutic modality – continues to grow.
  • CleanCap® technology is a one-pot solution with over 95% capping efficiency that streamlines mRNA production processes when compared to legacy capping methods.
  • “We’re thrilled to offer our innovative capping solutions to Lonza and its customers.”
    Since its launch in 2017, TriLink’s CleanCap® capping technology has continued to advance the mRNA capping industry and is used in a majority of approved mRNA and saRNA vaccines.
  • In May 2023, TriLink introduced its most robust CleanCap analog to date, CleanCap® M6 , with studies indicating increased mRNA expression by more than 30% versus enzymatic capping methods.

TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production

Retrieved on: 
Donnerstag, April 18, 2024
Other Health, Research, General Health, Pharmaceutical, Oncology, Infectious Diseases, Clinical Trials, Science, Medical Supplies, FDA, Other Science, Health, Safety, Cancer, Gene editing, NTP, Vaccine, CDMO, Melamaravakkadu, SaRNA, Biotechnology, Infection, Multimedia, Messenger, GMP, COVID-19, CGMP

TriLink BioTechnologies (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has announced the grand opening of its new cGMP mRNA manufacturing facility .

Key Points: 
  • TriLink BioTechnologies (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has announced the grand opening of its new cGMP mRNA manufacturing facility .
  • The 32,000-square-foot facility was specifically designed for mRNA manufacturing to support late-phase drug developers from Phase 2 to commercialization via TriLink’s robust mRNA manufacturing capabilities .
  • View the full release here: https://www.businesswire.com/news/home/20240418722567/en/
    TriLink BioTechnologies® Cuts Ribbon on New San Diego Facility for Late Phase mRNA Drug Substance Production (Photo: TriLink BioTechnologies®)
    Located in the Sorrento Valley area of San Diego, the facility features individual Grade C cleanroom suites for mRNA manufacturing, increased mRNA capacity (1g to >100g per batch), comprehensive in-house analytical services, and laboratory space for on-site quality control testing.
  • TriLink has reliably delivered GMP services to drug developers since the debut of its first cGMP facility in 2015.

Ractigen Therapeutics Announces FDA Approval for RAG-01, a First-in-Class saRNA Therapy for BCG-Unresponsive NMIBC

Retrieved on: 
Freitag, April 26, 2024
FDA, Food, RNA, Cell cycle, Growth, IND, Therapy, Patient, SaRNA, NMIBC, RNAa, Bladder cancer, Investigational New Drug

SUZHOU, China, April 26, 2024 /PRNewswire/ -- Ractigen Therapeutics, a leader in the development of small activating RNA (saRNA) therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application for RAG-01, a groundbreaking saRNA therapy targeting non-muscle invasive bladder cancer (NMIBC).

Key Points: 
  • SUZHOU, China, April 26, 2024 /PRNewswire/ -- Ractigen Therapeutics, a leader in the development of small activating RNA (saRNA) therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application for RAG-01, a groundbreaking saRNA therapy targeting non-muscle invasive bladder cancer (NMIBC).
  • This approval facilitates the launch of U.S. clinical trials, following the successful initiation of a Phase I trial in Australia.
  • "FDA IND approval for RAG-01 is a major achievement for Ractigen and a significant advancement for saRNA technology worldwide," said Dr. Long-Cheng Li, Founder and CEO of Ractigen Therapeutics.
  • This approval validates the potential of RAG-01 as a leading saRNA therapy and strengthens our position as innovators in RNA-based treatments."

TriLink BioTechnologies® Solidifies IP Position with Awarded Patents for CleanCap® Capping Technology in China and Canada

Retrieved on: 
Mittwoch, Februar 21, 2024
Research, Infectious Diseases, FDA, Genetics, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, Maker, Therapy, Messenger, CIPO, Vaccine, General counsel, ARCA, COVID-19, SaRNA, CNIPA, Intellectual property, Melamaravakkadu, Human

“mRNA technology continues to prove its value as a breakthrough modality for innovative medicines,” explained Drew Burch, President of Nucleic Acid Production at TriLink.

Key Points: 
  • “mRNA technology continues to prove its value as a breakthrough modality for innovative medicines,” explained Drew Burch, President of Nucleic Acid Production at TriLink.
  • CleanCap® technology has been used in commercially approved COVID-19 mRNA and saRNA vaccines.
  • “TriLink’s CleanCap technology is helping to bring life-saving therapeutics and vaccines to market faster,” added Kurt Oreshack, Executive Vice President & General Counsel, Maravai LifeSciences.
  • “These additional jurisdictions fortify the validity and strength of our global intellectual property.”
    Last May, TriLink launched its most robust analog to date: CleanCap® M6 .

Global Lipid Nanoparticle Manufacturing Market 2023-2035: Partnerships Surge in Lipid Nanoparticle Manufacturing as Moderna Collaborates with IBM for Cutting-Edge LNPs - ResearchAndMarkets.com

Retrieved on: 
Montag, Februar 12, 2024
Technology, Biotechnology, Nanotechnology, Health, Molecule, CMO, Infection, Growth, RNA, Phospholipid, Liposome, Solubility, Organization, Absorption, Integration, Therapy, Type, Levidian Nanosystems, Small RNA, Ionization, DNA, Partnership, Creative Biolabs, CMOS, Permeability, Sphingolipid, CDMO, SaRNA, Dicarboxylic acid, Antigen, Research, Emergent, Acquisition, Lipid, Messenger, PEGylation, IBM, Geography, Risk, Fresenius (company), Fujifilm, Triglyceride, Element, MicroRNA, Acuitas Therapeutics, Vaccine

This in turn will drive the market growth of lipid nanoparticle manufacturing market during the forecast period.

Key Points: 
  • This in turn will drive the market growth of lipid nanoparticle manufacturing market during the forecast period.
  • The report features an extensive study of the current market landscape, market size and future opportunities within the lipid nanoparticle manufacturing market, during the given forecast period.
  • Key takeaways of the lipid nanoparticle manufacturing (services and technologies) market report are briefly discussed below.
  • An in-depth analysis of the factors that can impact the growth of lipid nanoparticle manufacturing market.

Ractigen Therapeutics Advances into Clinical Stage with Groundbreaking saRNA Drug, RAG-01

Retrieved on: 
Mittwoch, Dezember 6, 2023
RNA, Bladder cancer, Therapy, Clinical trial, Pharmacokinetics, BCG, SaRNA, RNAa, Patient, Safety, NMIBC, Pharmaceutical industry

JIANGSU, China, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Ractigen Therapeutics, a leader in the field of small activating RNA (saRNA) therapeutics, is excited to announce the submission of a clinical trial application in Australia.

Key Points: 
  • JIANGSU, China, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Ractigen Therapeutics, a leader in the field of small activating RNA (saRNA) therapeutics, is excited to announce the submission of a clinical trial application in Australia.
  • This milestone marks Ractigen's transition into clinical development, with RAG-01 targeting NMIBC.
  • RAG-01 is recognized as the second saRNA drug worldwide to enter clinical trials and the first of its kind in China to achieve this critical milestone.
  • This development signifies a remarkable advancement in RNA-based therapeutic applications, especially in the context of challenging cancer treatments.

Ractigen Presents Preclinical Results of Its saRNA Therapeutic Targeting DMD/BMD at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting

Retrieved on: 
Donnerstag, November 2, 2023
OTS, SOD1, UTRN, Heart, RNA, BMD, Myopathy, CNS, RNAa, SaRNA, Mouse, MDX, ALS, Duchenne muscular dystrophy, Lead, SCAD, Gene, DMD, Oligonucleotide, Therapy, Patient, Small RNA, Mutation, Vaccine

JIANGSU, China, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ractigen Therapeutics, a clinical stage biopharmaceutical company founded by the pioneers in RNA activation (RNAa), presented recent preclinical results at the annual meeting of the Oligonucleotide Therapeutics Society (OTS) in Barcelona, Spain.

Key Points: 
  • JIANGSU, China, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ractigen Therapeutics, a clinical stage biopharmaceutical company founded by the pioneers in RNA activation (RNAa), presented recent preclinical results at the annual meeting of the Oligonucleotide Therapeutics Society (OTS) in Barcelona, Spain.
  • RNAa uses short duplex RNA known as saRNA to target and ‘turn up’ transcription of endogenous genes leading to restoration of their protein function.
  • "We are very excited about the preclinical results of our utrophin activating saRNA and believe that our approach could represent an ideal therapeutic strategy that benefits all DMD and BMD patients," said Long-Cheng Li, CEO of Ractigen Therapeutics.
  • The SCADTM platform has propelled Ractigen’s leading RNA program to the clinic for the treatment of ALS patients with SOD1 mutation.

RNA Therapeutics Market Poised for Explosive Growth: Estimated Worth Exceeds $1.1 Billion by 2035, with a Remarkable 50% CAGR from 2026-2035 - ResearchAndMarkets.com

Retrieved on: 
Dienstag, Oktober 17, 2023
Biotechnology, Infectious Diseases, Health, Genetics, Pharmaceutical, Transfer, Gene expression, Vaccine, Infection, Investment, Vertex Pharmaceuticals, Engineering, Sarcoidosis, RNA, USD, Therapy, Safety, SaRNA, Cystic fibrosis, Attenuated vaccine, Erna, Duchenne muscular dystrophy, Recode, Messenger, Circular RNA, Small RNA, China-ASEAN Investment Cooperation Fund, RNA therapeutics, Research, Pharmaceutical industry

The "RNA Therapeutics Market and RNA Vaccines Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "RNA Therapeutics Market and RNA Vaccines Market" report has been added to ResearchAndMarkets.com's offering.
  • Next Generation RNA Therapeutics and Vaccines: The market is witnessing the development of next-generation RNA therapeutics and vaccines that target diseases previously considered undruggable.
  • These include modalities such as circular RNA (circRNA), endless RNA (eRNA), self-activating RNA (sacRNA), self-amplifying RNA (saRNA), self-amplifying mRNA (samRNA), replicating RNA (repRNA), and transfer RNA (tRNA).
  • Investment and Funding: The market has attracted substantial investments, with over $2.9 billion raised or invested in RNA therapeutics and RNA vaccines development since 2019.

VaxEquity and CPI Announces Innovate UK Grant to Accelerate Next Generation RNA Vaccines and Therapeutics

Retrieved on: 
Montag, Juni 5, 2023
Vaccine, Death, Innovate UK, Dicarboxylic acid, Therapy, Biopharmaceutical, CPI, RNA, Innovation, SaRNA, The Mindsweep: Hospitalised

CAMBRIDGE, United Kingdom, June 05, 2023 (GLOBE NEWSWIRE) -- VaxEquity, developing transformative RNA vaccines and therapeutics based on its next generation self-amplifying RNA (saRNA) platform, and CPI, the UK’s leading independent technology innovation centre, today announce a grant of approximately £700K from Innovate UK.

Key Points: 
  • CAMBRIDGE, United Kingdom, June 05, 2023 (GLOBE NEWSWIRE) -- VaxEquity, developing transformative RNA vaccines and therapeutics based on its next generation self-amplifying RNA (saRNA) platform, and CPI, the UK’s leading independent technology innovation centre, today announce a grant of approximately £700K from Innovate UK.
  • The grant will fund a collaborative project to advance the manufacturing process for RNA vaccines and therapeutics.
  • Dr Tim Sparey, Managing Director at VaxEquity, said: “The potential of nucleic acids as vaccines and therapeutics is only just being realised.
  • This powerful collaboration with CPI, fuelled by Innovate UK, starts with a giant step forward in scaling the manufacturing of a novel saRNA influenza vaccine.

invoX Pharma Increases Investment in pHion Therapeutics to Further Develop Next Generation of mRNA Vaccines

Retrieved on: 
Donnerstag, Juni 1, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Nanoparticle, Workforce Investment Act of 1998, Infection, Cancer, Temperature, Prostate, Dicarboxylic acid, Messenger, CD8, SaRNA, Sino Biopharmaceutical Limited, HKEX, Trust, HPV-positive oropharyngeal cancer, Patient, RALA, HPV, Growth, Cervical cancer, Therapy, Vaccine

invoX Pharma Limited (“invoX”), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK) with an advancing pipeline of innovative products, today announced that it has completed a second tranche of investment in pHion Therapeutics (“pHion”), a next-generation mRNA vaccine company.

Key Points: 
  • invoX Pharma Limited (“invoX”), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK) with an advancing pipeline of innovative products, today announced that it has completed a second tranche of investment in pHion Therapeutics (“pHion”), a next-generation mRNA vaccine company.
  • The company’s proprietary RALA platform can deliver anionic molecules such as mRNA and saRNA in a stealth-like way, evading detection, to generate a potent antigen-specific CD8+ T-cell response.
  • Prof. Helen McCarthy, Chief Executive Officer and Founder of pHion, said:
    “At pHion Therapeutics, it is our mission to pioneer next generation, first-in-class vaccines for infectious disease and oncology through stealth-like delivery of mRNA.
  • We look forward to seeing PTX_V1 reach the clinic and supporting this program into the next stages of its development.”